WO2018074606A1 - ラミニン511産生促進剤、表皮基底膜安定化剤及び/又は表皮幹細胞減少抑制又は増加促進剤のスクリーニング方法 - Google Patents
ラミニン511産生促進剤、表皮基底膜安定化剤及び/又は表皮幹細胞減少抑制又は増加促進剤のスクリーニング方法 Download PDFInfo
- Publication number
- WO2018074606A1 WO2018074606A1 PCT/JP2017/038079 JP2017038079W WO2018074606A1 WO 2018074606 A1 WO2018074606 A1 WO 2018074606A1 JP 2017038079 W JP2017038079 W JP 2017038079W WO 2018074606 A1 WO2018074606 A1 WO 2018074606A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- laminin
- epidermal
- expression
- cells
- algae
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01166—Heparanase (3.2.1.166)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- the present invention relates to the technical field of suppressing or promoting the decrease in epidermal stem cells in the epidermal basement membrane.
- the epidermis is the skin tissue present in the outermost layer of the skin.
- the epidermis is mainly composed of a stratum corneum, a granular layer, a spiny layer, and a basal layer.
- Basal cells present in the basal layer divide and migrate to the outer layer. In the process of migration, enucleation occurs in the cells, flattenes and differentiates into the stratum corneum, and the stratum corneum finally peels off.
- the turnover period is said to be about 45 days.
- the turnover speed is slow and the entire epidermis is thinned. As a result, it is known that skin functions such as barrier function and moisture content are reduced.
- a basal cell is a cell that is rich in mitotic properties, but it does not repeat indefinitely, and it does not divide after a certain number of divisions. Basal cells are newly supplied by differentiation of part of epidermal basal stem cells present on the basement membrane. However, it is known that the number of epidermal basal stem cells decreases with aging, and when the number of epidermal basal stem cells decreases, it may show signs of aging such as thinning of the epidermis, drying of the epidermis, and reduced barrier function. become.
- MCSP antibody which is a marker of epidermal basal stem cells
- epidermal basal stem cells by using this antibody, epidermal basal stem cells can be identified.
- Epidermal basal cell visualization using MCSP antibody has been performed on the skin of unexposed areas of men and women of each age, and it has been shown that the number of MCSP-positive epidermal basal stem cells decreases with aging (Non-Patent Literature). 1). Development of a drug having an action of promoting an increase in the number of MCSP-positive epidermal basal stem cells or an action of suppressing a decrease is demanded.
- An object of the present invention is to provide a technique for promoting or increasing the number of MCSP positive epidermal basal stem cells.
- the present inventors conducted extensive studies on MCSP-positive epidermal basal stem cells, and found a relationship between MCSP-positive epidermal basal stem cells and laminin 511 present in the vicinity of the basement membrane. That is, when laminin 511 near the basement membrane decreases, the number of MCSP-positive epidermal basal stem cells also decreases accordingly, and it has been found for the first time that the number of MCSP-positive epidermal basal stem cells can be increased by increasing the expression level of laminin 511. .
- laminin is a complex of laminin ⁇ , ⁇ and ⁇ , and it has been found that the abundance of laminin 511 can be determined by using the expression levels of laminin ⁇ 5, ⁇ 1, and ⁇ 1 as an index.
- the inventors have reached an invention relating to a method for screening a laminin 511 expression promoter using the expression of laminin 511 as an index. Since the laminin 511 expression promoter can stabilize the basement membrane, the screening method for the laminin 511 expression promoter can also be referred to as a screening method for the basement membrane stabilizer. Further, when the abundance of laminin 511 is increased and the basement membrane is stabilized, the epidermal basal stem cells are increased or decreased, and the screening method for laminin 511 expression promoter promotes the increase of epidermal basal stem cells. It can also be referred to as a screening method for agents or reduction inhibitors.
- the expression level of laminin 511 is determined from the amount of one or more mRNAs selected from the group consisting of the amount of laminin 511 protein or the amount of laminin ⁇ 5 mRNA, the amount of laminin ⁇ 1 mRNA, and the amount of laminin ⁇ 1 mRNA.
- the laminin 511 expression promoter is an epidermal basement membrane stabilizer.
- the epidermal basement membrane stabilizer is an agent for suppressing or increasing epidermal basal stem cell decrease.
- the epidermal cells comprise epidermal stem cells.
- the epidermal stem cell comprises an epidermal basal stem cell.
- the epidermal cells comprise MCSP-expressing cells.
- the epidermal cell further comprises a cell expressing integrin.
- Epidermis base by promoting the expression of laminin 511 containing at least one extract selected from the group consisting of brown algae, red algae and green algae or 1- (2-hydroxyethyl) -2-imidazolidinone as an active ingredient
- An activity inhibitor of extracellular matrix degrading enzyme comprising 1- (2-hydroxyethyl) -2-imidazolidinone.
- a laminin 511 degradation inhibitor comprising the extracellular matrix degrading enzyme activity inhibitor according to any one of items 15 to 17.
- An epidermal basement membrane stabilizer comprising the extracellular matrix degrading enzyme activity inhibitor according to any one of items 15 to 17.
- laminin 511 in the epidermis comprising administering at least one extract selected from the group consisting of brown algae, red algae, and green algae or 1- (2-hydroxyethyl) -2-imidazolidinone. Enhancement method.
- At least one extract or 1- (2-hydroxyethyl) -2-imidazolidinone selected from the group consisting of brown algae, red algae, and green algae is administered, and the laminin 511 expression promoting action causes the epidermal base. Method to stabilize the membrane.
- At least one extract selected from the group consisting of brown algae, red algae, and green algae or 1- (2-hydroxyethyl) -2-imidazolidinone is administered, and the expression promoting action of laminin 511 causes the epidermal base.
- a method of suppressing or promoting an increase in stem cell loss is administered.
- a skin barrier, firmness, moisture, and inflammation improving agent comprising at least one extract selected from the group consisting of brown algae, red algae, and green algae.
- An inflammation inhibitor comprising at least one extract selected from the group consisting of brown algae, red algae, and green algae.
- Use of at least one extract selected from the group consisting of brown algae, red algae, and green algae for the production of an inflammation inhibitor.
- a skin comprising applying a cosmetic comprising at least one extract selected from the group consisting of brown algae, red algae, and green algae to a subject in need of improvement in skin barrier, elasticity, moisture, and inflammation. Cosmetic methods for improving barriers, firmness, moisture and inflammation.
- a cosmetic method for suppressing inflammation comprising applying a cosmetic comprising at least one extract selected from the group consisting of brown algae, red algae, and green algae to a subject suffering from inflammation.
- FIG. 1A is a diagram showing the expression of MCSP in the abdomen (non-exposed part) and face part (exposed part) of the 20s, and the abdomen (non-exposed part) and face part (exposed part) of the 60s.
- FIG. 1B is a graph obtained by measuring and comparing the number of MCSP positive cells with respect to the length of the basement membrane in skin sections of the abdomen (non-exposed part) and face part (exposed part) of subjects of each age.
- FIG. 1C is a graph comparing the expression level of MCSP in skin sections of subjects of each age.
- FIG. 2A shows the expression of laminin 332, laminin 551, and ⁇ 1 integrin in the abdomen (non-exposed part) and face part (exposed part) of the twenties and the abdomen (non-exposed part) and face part (exposed part) of the 60s.
- FIG. 2B is a graph comparing the expression levels of laminin ⁇ 5 in skin sections of subjects of each age.
- FIG. 3A is a diagram showing the influence on the expression of MCSP when a culture plate is coated with laminin 511 during epidermal culture.
- FIG. 3B is a graph showing the effect on gene expression of a stem cell marker composed of CD46, Lrig1, DLL1, and CD44 when a culture plate is coated with laminin 511 during epidermal culture.
- FIG. 4A shows that laminin 511 is decreased by culturing human skin tissue.
- MMP inhibitor N-hydroxy-2 (R)-[[(4-methoxy- phenyl) sulfonyl] (3-picolyl) amino ] -3-methylbutanamide hydrochloride (hereinafter CGS27023A) and a heparanase inhibitor (1- [4- (1H-Benzoimidazol-2-yl) phenyl] -3- [4- (1H-benzoimidazol-2-yl) phenyl] urea, It is a figure which shows that laminin 511 is strengthened when BIPBIPU) is added.
- FIG. 4B shows that MCSP is decreased by human skin tissue culture, and that MCSP is maintained or enhanced when an MMP inhibitor (CGS27023A) and a heparanase inhibitor (BIPBIPU) are added.
- CCS27023A MMP inhibitor
- BIPBIPU heparanase inhibitor
- FIG. 5A is a graph showing that the gene expression of laminin ⁇ 5, laminin ⁇ 1, and laminin ⁇ 1 increases in a dose-dependent manner by the addition of Algerex.
- FIG. 5B is a graph showing that the amount of laminin ⁇ 5 chain protein increases in a dose-dependent manner by the addition of Algerex.
- FIG. 6 is a graph showing changes in gene expression due to the addition of Algerex.
- Heparanase (HPA) gene FIG.
- FIG. 6A is a diagram showing the effect of laminin 511 and MCSP on protein expression by addition of 1- (2-hydroxyethyl) -2-imidazolidinone (HEI) in exovivo human skin organ culture.
- FIG. 8 is a graph showing the heparanase inhibitory activity of 1- (2-hydroxyethyl) -2-imidazolidinone (HEI).
- FIG. 9 is a diagram showing the inhibitory activity of 1- (2-hydroxyethyl) -2-imidazolidinone (HEI) on MMP9.
- FIG. 10A is a graph showing changes in filaggrin protein expression due to the addition of 1- (2-hydroxyethyl) -2-imidazolidinone (HEI) in ex-vivo human skin organ culture.
- FIGS. 10B and 10C are graphs showing changes in TEWL and stratum corneum moisture content due to the addition of 1- (2-hydroxyethyl) -2-imidazolidinone (HEI) in ex-vivo human skin organ culture.
- FIGS. 10A is a graph showing changes in filaggrin protein expression due to the addition of 1- (2-hydroxyethyl) -2-imidazolidinone (HEI) in ex-vivo human skin organ culture.
- FIGS. 10B and 10C are graphs showing changes in TEWL and stratum corneum moisture content due to the addition of 1- (2-hydroxyethyl
- FIG. 10D and E are graphs showing changes in TEWL and stratum corneum moisture content due to 1- (2-hydroxyethyl) -2-imidazolidinone (HEI) in an in vivo single-shielded human continuous test.
- FIG. 11A is an electron micrograph immediately below the basement membrane when an MMP inhibitor (CGS27023A) and a heparanase inhibitor (BIPBIPU) are added in organ culture of skin tissue. A cross section of the collagen fiber is shown below the basement membrane.
- FIG. 11B is a histogram showing the diameter and frequency of collagen fibers measured on an electron micrograph.
- FIG. 11C shows the mean value of the fiber diameter on the electron micrograph.
- FIG. 11D is a graph showing the average value of the density of fibers on an electron micrograph.
- FIG. 12A is a fluorescence micrograph showing the expression of type V collagen and the expression of K-14 indicating keratinocytes in skin samples obtained from young (29 years) and old (60 years) subjects.
- FIG. 12B is a graph showing the expression level of the gene COL5A1 for V-type collagen in keratinocytes and fibroblasts obtained from young subjects, and keratinocytes and fibroblasts obtained from old subjects.
- FIG. 13A shows the expression of type V collagen and the expression of K-14 indicating keratinocytes by the addition of an MMP inhibitor (CGS27023A) and a heparanase inhibitor (BIPBIPU) in an organ culture of skin tissue and a three-dimensional model of skin. It is a fluorescence micrograph shown.
- FIG. 13B is a graph showing expression of gene COL5A1 of type V collagen in the dermis of a three-dimensional skin model.
- FIG. 13C is an electron micrograph focusing on fibroblasts directly under the basement membrane when an MMP inhibitor (CGS27023A) and a heparanase inhibitor (BIPBIPU) are added in organ culture of skin tissue.
- FIG. 14 shows that culture supernatant collected from a culture of a three-dimensional model of skin cultured with MMP inhibitor (CGS27023A) and heparanase inhibitor (BIPBIPU) added to cultured dermal fibroblasts. It is a graph which shows gene COL5A1 expression of the type V collagen in the case.
- FIG. 15 is a graph showing expression of the gene COL5A1 of type V collagen when PDGF-BB is added to cultured human fibroblasts.
- FIG. 16A is a fluorescence micrograph showing the expression of PDGFR ⁇ and the expression of K-14 indicating keratinocytes in skin samples obtained from young (32 years) and old (68 years) subjects.
- FIG. 16B is a graph showing the expression level of the PDGF-BB protein gene PDGFB in normal human epidermal cells of each age.
- the present invention relates to a method for screening a laminin 511 expression promoter using the expression of laminin 511 in epidermal cells as an index. More specifically, the screening method for laminin 511 expression promoter is as follows: Culturing epidermal cells in a culture medium containing a candidate drug; Measuring the expression of laminin 511 in epidermal cells, A step of determining that the candidate drug has a laminin 511 expression promoting effect when the expression of laminin 511 is increased as compared with the expression level of laminin 511 in the control. Furthermore, you may include the process of irradiating a cultured epidermal cell with an ultraviolet-ray.
- the expression level of laminin 511 is decreased by irradiation with ultraviolet rays.
- irradiation with ultraviolet rays can be performed by irradiating cultured cells at 1 mJ / cm 2 to 200 mJ / cm 2 .
- Irradiation with ultraviolet light enhances the activity of matrix metalloproteinases and can lead to degradation of laminin. Therefore, when the candidate drug can suppress the decrease in the protein amount of laminin 511 under ultraviolet irradiation, it can be seen that the candidate drug has a laminin 511 degradation inhibitory effect and an expression promoting effect.
- the candidate drug has an effect of promoting the expression of laminin 511.
- the step of culturing the epidermal cells in the culture medium containing the candidate drug may be performed in any manner as long as the culture medium containing the candidate drug and the cultured epidermal cells are in contact.
- the candidate drug or a diluted solution thereof may be added directly to the culture medium, or the medium may be replaced with a medium containing the candidate drug.
- Culturing is performed under normal conditions used for culturing human epidermal cells. As an example, the cells are cultured in an incubator at 37 ° C. in a humidified atmosphere of 5% CO 2 .
- the culture time after the addition of the candidate drug can be arbitrarily set according to the effect of the candidate drug.
- the culture can be performed, for example, for 300 minutes or longer, preferably 6 hours or longer, more preferably 48 hours or longer. Further, from the viewpoint of preventing saturation of the effect of the candidate drug, for example, the culture can be performed for a period of 7 days or less, preferably 5 days or less, more preferably 72 hours or less.
- Measurement of laminin 511 expression in cultured epidermal cells can be performed using an antibody that recognizes laminin 511 and using any technique of molecular biology. For example, Western blotting or immunostaining can be used to measure the amount of laminin 511 protein. Moreover, the expression of laminin 511 can be measured based on the mRNA transcription amount of the constituent subunits ( ⁇ 5, ⁇ 1, ⁇ 1) of laminin 511. For example, the amount of mRNA transcription can be measured by Northern blotting or quantitative PCR. The constituent subunits can be measured based on any one transcription amount, or can be measured as a combination of two or three transcription amounts.
- the expression level can be measured by summing the expression levels of laminin ⁇ 5, laminin ⁇ 1, and laminin ⁇ 1. In another embodiment, the amount of the constituent subunit having the lowest expression level can be the expression level of laminin 511.
- the candidate drug has a laminin 511 expression promoting effect.
- the candidate drug has a laminin 511 expression promoting effect.
- the expression level increases at a predetermined rate, it can be determined that the candidate drug has a laminin 511 expression promoting effect.
- the predetermined ratio can be arbitrarily determined by those skilled in the art, but for example, 10%, more preferably 20%, still more preferably 30%, and even more preferably 50% compared to the expression level of the control.
- the determination step is preferably performed by a computer that includes an instrument that has performed expression measurement or a processor that has acquired data from the instrument.
- the expression level of laminin 511 in the control refers to the expression level of laminin 511 in epidermal cells subjected to the same operation except that the candidate drug is not included. Therefore, the above-described culture step and expression measurement step may include a step of culturing a control epidermal cell in a culture medium not containing a candidate drug and measuring the expression of laminin 511 in the control epidermal cell.
- the culture process and the expression process for the control may be performed in parallel with the culture process and the expression process using the culture medium containing the candidate drug, or may be performed in advance.
- the screening process of the present invention includes, in addition to the above-described processes, a pre-culture process performed before the process of culturing epidermal cells in a culture medium containing a candidate drug, and a process of culturing epidermal cells in a culture medium containing a candidate drug
- a post-cultivation step that is later cultured in a culture medium that does not contain a candidate drug, a recovery step that recovers cells, a recovered cell, or a protein extracted from the recovered cell, mRNA, or DNA reverse-transcribed from mRNA Can include any additional steps such as storing.
- Laminin is a protein belonging to the laminin family and is one of the proteins constituting the basement membrane.
- laminin 332 composed of ⁇ 3 ⁇ 3 ⁇ 2 subunits and laminin 511 composed of ⁇ 5 ⁇ 1 ⁇ 1 subunits are known to exist in the basement membrane.
- Laminin is recognized by integrins expressed on cells and functions as a cell scaffold. Based on laminin present in the basement membrane, epidermal basal cells form a layer.
- Laminin 511 is a protein involved in cell adhesion and proliferation, and is mainly present in the epidermal basement membrane.
- Laminin 511 has a binding property to ⁇ 1 integrin, particularly ⁇ 6 ⁇ 1 integrin. In cell experiments, it is involved in the growth of stem cells that express ⁇ 1 integrin and is used for culturing iPS cells and ES cells. In the living body, laminin 511 is known to decrease with aging. The present inventors have revealed that laminin 511 decreases due to the influence of ultraviolet rays in addition to aging (FIG. 1). While not intending to be limited by theory, it is believed that ultraviolet light activates matrix metalloproteinase (MMP), thereby reducing laminin levels.
- MMP matrix metalloproteinase
- laminin 332 is less affected by aging and ultraviolet rays, while laminin 511 decreases with aging and further decreases due to the influence of ultraviolet rays (FIG. 2A).
- This tendency shows the same tendency as that of ⁇ 1 integrin expressed in stem cells, and the same tendency was observed for MCSP-expressing stem cells (FIG. 1A).
- the laminin 511 expression promoter can be interpreted in the broadest sense, and can include any drug as long as it is a drug that can increase the amount of laminin 511 protein. Therefore, not only a drug that can promote the gene expression of laminin 511 but also a drug that increases the protein amount of laminin 511 by a heparanase inhibitory action or an MMP inhibitory action can be called a laminin 511 expression promoter.
- Laminin 511 expression can be determined by the amount of protein or mRNA. Since laminin 511 is a complex protein, the laminin 511 expression promoter can promote the expression of each mRNA of the constituent subunits.
- the laminin 511 expression promoting agent can exert an epidermal basement membrane stabilizing effect, an epidermal stem cell decrease inhibiting effect, and an epidermal stem cell increase promoting effect by increasing the expression of laminin 511 in the epidermal basement membrane. Therefore, the laminin 511 expression promoter can also be referred to as an epidermal basement membrane stabilizer, an epidermal stem cell decrease inhibitor, or an epidermal stem cell increase promoter.
- the epidermal basement membrane exists in the lowermost layer of the epidermis and constitutes the boundary between the epidermis and the dermis.
- the epidermal basement membrane is a thin membrane-like extracellular matrix mainly composed of collagen, proteoglycan, entactin and laminin. Basal cells are arranged on the basement membrane, and the basement membrane and the basement cells are called the basal layer of the epidermis.
- the basement membrane mainly contains type I collagen, type IV collagen, and type VII collagen as collagen.
- the basement membrane mainly includes laminin 511 and laminin 332 as laminin.
- the basement membrane is partially degraded and destabilized by the influence of extracellular matrix degrading enzymes such as matrix metalloproteinase and heparanase.
- epidermal cells that proliferate using laminin as a cell scaffold such as ⁇ 1-integrin-expressing cells
- epidermal stem cells especially basal epidermal stem cells, are considered to be ⁇ 1 integrin-expressing cells, and these cells can be lost with a decrease in laminin.
- the collagen contained in the dermis has a different shape depending on the position in the dermis, and the type of collagen that is composed is also different.
- the epidermis basement membrane region contains type I collagen, type IV collagen, and type VII collagen, and in the region directly below the basement membrane, a thin collagen fiber bundle called a fibrous reticulum is located and goes deeper. As the collagen fine fibers are located, thick collagen fibers are located in the deepest part.
- the fiber reticular plate in the region immediately below the basement membrane is mainly composed of type V collagen, the collagen fibrils are composed of type III collagen and type V collagen, and the deepest collagen fibers are type I and type III. Consists of collagen.
- type V collagen directly under the basement membrane is produced by dermal fibroblasts in the dermis layer
- the study by the present inventors showed that it decreases in an age-dependent manner (FIG. 12).
- the presence of type V collagen is closely related to the presence of the basement membrane (FIG. 13A).
- the collagen production amount as a whole dermis layer was not affected by the addition of an MMP inhibitor or a heparanase inhibitor that protects the basement membrane (FIG. 13B). Based on these results, the present inventors have hypothesized that when a factor is secreted from the basement membrane side, only the dermal fibroblasts directly under the basement membrane are activated and produce type V collagen. It was.
- the epidermis was collected from a culture of a three-dimensional skin model to which an MMP inhibitor that protects the basement membrane and a heparanase inhibitor was added, and when attention was paid to a growth factor whose expression changed with or without the addition of an inhibitor, PDGF-BB was These were identified as growth factors having an action of promoting expression of type V collagen (FIG. 15).
- PDGFR ⁇ a receptor for PDGF-BB, was shown to be expressed in dermal fibroblasts directly under the basement membrane.
- the laminin 511 expression promoter, epidermal basement membrane stabilizer, epidermal stem cell decrease suppression or increase promoter specified by the present invention can also be referred to as a PDGF-BB production promoter, It can also be used as a collagen production promoter, particularly preferably as a V-type collagen production promoter, and can be blended in cosmetics as a firmness improving agent.
- the epidermal basement membrane stabilizer refers to a drug that can stabilize the epidermal basement membrane.
- the basement membrane stabilizer may be an inhibitor of an extracellular matrix degrading enzyme that degrades the basement membrane, or may be an expression promoter for a basement membrane constituent molecule.
- Inhibitors of extracellular matrix degrading enzymes include heparanase inhibitors, for example, drugs such as Mukuroji extract powder, valerian extract E, shampoo extract BG, white lily, long-life herbal extract, IBR, S-173, and BIBIPU. ing.
- MMP matrix metalloproteinase
- drugs such as turmeric extract BG, tormentilla extract, mangosteen extract BG, and CGS27023A are known.
- Reduction of epidermal basal stem cells can be suppressed or proliferated through stabilization of the epidermal basement membrane. Therefore, the epidermal basement membrane stabilizer can also be referred to as an epidermal basal stem cell decrease inhibitor or an increase promoter.
- An agent for suppressing or increasing epidermal basal stem cell decrease refers to an agent capable of exerting an effect of suppressing or maintaining the proliferation, decrease or maintenance of epidermal basal stem cells.
- the anti-aging action of the epidermis can be exerted through an agent for suppressing or increasing the number of epidermal basal stem cells. Therefore, the epidermis basement membrane stabilizer can also be referred to as a skin anti-aging agent.
- the epidermal stem cell decrease suppression or increase promoter of the present invention refers to a drug that can suppress, maintain, or increase the decrease of epidermal stem cells in the skin.
- the number of epidermal stem cells decreases with aging and ultraviolet irradiation, the decrease in epidermal stem cells can be suppressed or maintained by applying the epidermal stem cell decrease suppression or increase promoter of the present invention. In another embodiment, the number of epidermal stem cells can be increased.
- the epidermal cells used in the present invention can be cultured epidermal cells.
- the epidermal cells can include keratinocytes, Langerhans cells, Merkel cells, melanocytes, and epidermal basal cells, and preferably include epidermal stem cells. More preferably, such epidermal stem cells are preferably epidermal stem cells expressing MCSP, that is, epidermal basal stem cells.
- epidermal stem cells in addition to epidermal basal stem cells, it is considered that epidermal stem cells are also present in the bulge region and sebaceous gland.
- epidermal basal stem cells can express MCSP. Therefore, MCSP-expressing epidermal stem cells usually refer to epidermal basal stem cells.
- the epidermal cells preferably express integrins.
- integrin to be expressed include ⁇ integrin and ⁇ integrin.
- epidermal stem cells preferably express ⁇ 1 integrin.
- Epidermal cells may be cells derived from any animal species, but human cells are preferred for the purpose of eliminating the effects of each species.
- the human cultured cells may be of any origin such as adults, children, infants, infants, infants, newborns, and fetuses, but are preferably derived from fetuses from the viewpoint of using cells containing a large amount of basal stem cells.
- Integrins expressed in epidermal cells are molecules that exist in the cell membrane and function as receptors for the extracellular matrix. Integrins are composed of an ⁇ chain and a ⁇ chain. About 18 types of ⁇ chain have been found, and about 8 types of ⁇ chain have been found.
- ⁇ 1 integrin refers to an integrin in which the ⁇ chain is a ⁇ 1 subunit and the ⁇ chain is an arbitrary subunit. An integrin containing a ⁇ 1 subunit has a high binding property to laminin.
- stem cells expressing ⁇ 1 integrin are also lost due to the loss of laminin 511 due to the effects of aging and ultraviolet rays, resulting in a decrease in the number of MCSP-expressing stem cells.
- Candidate drugs can be drugs included in any library of cosmetics and medicines.
- libraries arbitrary libraries such as a compound library and an extract library can be used.
- an agent that can increase the expression of laminin 511 among the candidate agents it can be screened as a laminin 511 expression promoter, epidermal basement membrane stabilizer, epidermal basal stem cell decrease suppressor or increase promoter.
- Control refers to an experimental group that produces a laminin 511 expression level as a reference for comparison used to determine the laminin 511 expression promoting effect of a candidate drug in the determination step. Therefore, the expression level of laminin 511 determined using cultured cells cultured for the same period under the same conditions without including only the candidate drug is used as a control expression level for comparison.
- the expression level of such a control may be determined by culturing cells in parallel with the step of culturing epidermal cells in a culture medium containing a candidate drug, and measuring the expression of laminin 511. It may be determined by culturing for the same period under conditions and measuring the expression of laminin 511.
- Algerex was selected as a drug having a laminin 511 production promoting effect.
- the drug thus selected is a laminin 511 expression promoter, epidermal basement membrane stabilizer, epidermal basal stem cell decrease inhibitor, and epidermal basal stem cell increase promoter.
- Algerex is a cosmetic ingredient sold by Ichimaru Falcos Co., Ltd. and relates to seaweed extract. More specifically, Argelex relates to a mixed extract of brown algae, red algae and green algae.
- the brown algae extract obtained by immersing all the algae of brown algae in 50% 1,3-butylene glycol for 3 days and filtering, and the total algae of brown algae, red algae and green algae into 50% 1,3 -It is obtained by immersing in butylene glycol for 3 days and mixing the extract of brown algae, red algae and green algae obtained by filtration.
- Argelex is thought to improve the moisture content and to exert an inhibitory effect on rough skin.
- the brown algae used for Algerex are algae of the genus Kumbu and Wakame, and are, for example, honey comb and wakame.
- the red algae used for Algerex are algae belonging to the genus Muchadenori, and examples thereof are giraffe and hijirimen.
- the green algae used for Argelex is algae of the genus Aosa, and is, for example, Usba aonori.
- the seaweed extract relates to an extract extracted from at least one algae selected from the group consisting of brown algae, red algae, and green algae.
- the seaweed extract relates to an extract of brown algae, red algae, and green algae.
- extract extracts of Kombu and Wakame genus brown algae, Mucadenori genus Red algae, and Aosa genus green algae are more preferred.
- Argelex is an extract extracts of Kombu and Wakame genus brown algae, Mucadenori genus Red algae, and Aosa genus green algae.
- the solvent used may be any solvent, and water, alcohol, ether, ester and the like can be used alone or in combination.
- monohydric alcohols such as methanol, ethanol, propanol and butanol
- dihydric alcohols such as ethylene glycol, propylene glycol and butylene glycol
- trihydric alcohols such as glycerin
- ether dimethyl ether, diethyl ether, ethyl methyl ether, tetrahydrofuran or the like
- ester methyl acetate, ethyl acetate or the like may be used. When used as a mixture, it can be used in any mixing ratio.
- a mixture of water and 1,3-butylene glycol can be used in the range of 1:10 to 10: 1, and more preferably in the range of 3:10 to 10: 3.
- a 1: 1 mixture may be used.
- the seaweed extract can be blended in cosmetics. For example, an amount of 0.0001% to 10%, preferably 0.001% to 1.0% of seaweed extract can be added to the cosmetic. As an example, 0.01% seaweed extract can be blended in cosmetics such as beauty essence, lotion, milky lotion, and cream.
- the seaweed extract of the present invention screened as a laminin 511 expression promoter exhibits a laminin 511 expression promoting effect, a basement membrane stabilizing effect, and an epidermal stem cell proliferation promoting or decreasing inhibitory effect. Also, due to these effects or independently, the seaweed extract suppresses the expression of the heparanase gene. Thereby, the improvement effect of a skin barrier function is exhibited. Therefore, the laminin 511 expression promoter containing seaweed extract can also be used as a heparanase gene expression inhibitor or skin barrier function improving agent.
- the seaweed extract increases the expression of the hyaluronic acid synthase 2 gene and suppresses the expression of the hyaluronidase gene. Thereby, the moisture of skin improves. Therefore, the laminin 511 expression promoter containing seaweed extract can also be used as a hyaluronic acid increase promoter or a skin moisture improver. Also, due to these effects or independently, seaweed extract extracts increase the expression of PDGF-BB. Since PDGF-BB acts on dermal fibroblasts to promote the production of collagen, particularly V-type collagen, laminin 511 expression promoting agents including seaweed extract extract exerts an effect of improving elasticity (in vivo) Medical Engineering (2017) 55 (2): 97-102).
- PDGF-BB is known to contribute to the stabilization of mesenchymal stem cells.
- Mesenchymal stem cells include dermal stem cells, and PDGF-BB acts on dermal stem cells and exerts an effect of improving elasticity. Therefore, the laminin 511 expression promoter containing seaweed extract can also be used as a PDGF-BB expression promoter or elasticity improving agent.
- seaweed extract extracts suppress the expression of IL-8. Thereby, the inflammation suppression effect is exhibited. Therefore, the laminin 511 expression promoter can also be used as an IL-8 expression inhibitor or inflammation inhibitor. Therefore, the seaweed extract can also be referred to as a skin barrier, firmness, moisture, and inflammation improving agent, and can be applied to a subject suffering from or in need of improvement of the skin barrier, elasticity, moisture, and inflammation.
- the present invention relates to a cosmetic method for improving at least one, preferably all, of skin barrier, firmness, moisture and inflammation.
- a cosmetic method comprises a cosmetic comprising at least one extract selected from the group consisting of brown algae, red algae, and green algae, suffering from at least one, preferably all of skin barrier, firmness, moisture, and inflammation, or Including applying to subjects in need of improvement.
- Such subjects include at least one of 1) reduced hyaluronic acid in the skin, 2) reduced skin barrier function, 3) onset of inflammation, 4) reduced fiber mass in the papillary layer, and 5) reduced PDGF-BB production.
- a subject suffering from or in need of improvement of at least one, preferably all, of skin barrier, firmness, moisture, and inflammation is reduced skin moisture, rough skin, pigmentation and skin darkening, It is also a subject suffering from symptoms such as reduced skin flexibility.
- an appropriate amount can be applied to the subject's face and body surface at least once a day, preferably at least twice a day. Particularly preferred embodiments are after bathing, before going to bed, and / or Or it can be applied after waking up.
- HEI 2-hydroxyethyl-2-imidazolidinone
- HEI has the following chemical formula: It is a compound represented by these.
- HEI was shown to have heparanase inhibitory activity and MMP9 inhibitory activity (FIGS. 8 and 9).
- HEI has an effect of promoting the expression of laminin 511 and an effect of maintaining ⁇ MCSP positive stem cells (FIG. 7).
- the effect of promoting the expression of laminin 511 can be exerted by heparanase inhibition and MMP9 inhibition activity, and thereby an ⁇ MCSP positive stem cell maintenance effect can be exerted. Therefore, the present invention relates to a laminin 511 expression promoter containing HEI.
- HEI extracellular matrix degrading enzyme inhibitor
- HEI extracellular matrix degrading enzyme inhibitor
- MMP9 extracellular matrix degrading enzyme inhibitor
- the MMP9 inhibitor can be used as an angiogenesis inhibitor, and thereby has cancer cell growth inhibitory action. Therefore, the heparanase and MMP9 activity inhibitors and basement membrane stabilizers in the present invention are used not only in cosmetics but also in medicine as cancer metastasis inhibitors, angiogenesis inhibitors, and cancer cell growth inhibitors.
- the laminin 511 expression promoter, epidermal basement membrane stabilizer, and epidermal basal stem cell decrease suppression or increase promoter screened in the present invention can each be incorporated into cosmetics as a cosmetic material.
- Cosmetics containing this cosmetic material are anti-aging to the epidermis through promoting the expression of laminin 511, through stabilizing the epidermal basement membrane, or through suppressing or promoting the increase in epidermal basal stem cells. An action or an anti-ultraviolet action can be exhibited.
- cosmetics it can be blended into any cosmetics, such as beauty essence, lotion, milky lotion, cream, body milk, bathing agent, sunscreen, makeup base, makeup product, lotion, after shaving cream, etc. Can be used.
- Such pharmaceuticals can be administered by any route such as oral, transdermal, intramuscular, intravenous, etc., but are preferably administered transdermally from the viewpoint of acting directly on the skin. It is preferably formulated into a topical skin preparation, a skin patch or the like for administration by transdermal administration. In particular, it can be blended into a skin external preparation.
- Agents that can be generally added to these cosmetics and pharmaceuticals such as humectants, whitening agents, antioxidants, oil components, UV absorbers, surfactants, thickeners, alcohols, coloring agents, fragrances, water, solvents, antiseptics Agents, preservatives, pH adjusters, gelling agents, and other active ingredients.
- the reduction of epidermal stem cells can be related to the aging phenomenon of the epidermis in all aspects. Examples of aging of the epidermis include reduction in moisture, rough skin, uneven color, and reduction in skin firmness. These aging phenomena are caused by a decrease in hyaluronic acid, a decrease in skin barrier function, inflammation, and a decrease in production of papillary fibrils and PDGF-BB, respectively. All of these aging phenomena can be solved by suppressing or promoting the decrease in the number of epidermal basal stem cells.
- the laminin 511 expression promoter, epidermal basement membrane stabilizer, and epidermal basal stem cell decrease suppression or increase promoter are filaggrin gene expression promoting effect, skin barrier function improving effect, moisture content improving effect, hyaluronic acid increasing, respectively. It can also be referred to as an anti-aging agent having one or more actions selected from the group consisting of action, inflammation sedation action, and papillary fiber and PDGF-BB production promotion action. Further, laminin 511 expression promoter, epidermal basement membrane stabilizer, and epidermal basal stem cell decrease suppression or increase promoter are filaggrin gene expression promoter, skin barrier function improver, water content enhancer, hyaluronic acid increase, respectively. It can also be referred to as an agent, an inflammation sedative, and a nipple layer fiber or PDGF-BB production promoter.
- Example 1 Sample of measurement of age-related changes in MCSP-positive epidermal basal stem cells in human skin and the influence of ultraviolet rays Subjects in their 20s to 70s who performed informed consent (20s: 9 people, 30s: 10 people, 40 people) Teenagers, 50s :: 9, 60s: 10, and 70s: 9), and skin samples of face and abdomen are obtained, fixed with cold acetone according to AMex method, and paraffin Embedded.
- FIG. 1A shows the staining results of the face and abdomen in the test subjects in their 20s and in their 60s.
- epidermal basal stem cells MCSP-positive basal cells present in the epidermal basal layer in subjects in their 20s and 60s was increased in both the face and abdomen. It was found to decrease with age. Moreover, it was found from the comparison between the facial part (exposed part) and the abdominal part (non-exposed part) in the same subject that the number of epidermal basal stem cells was small in the facial part (exposed part). Further, in each subject, the number of epidermal basal stem cells relative to the length of the basement membrane was measured, and the average was graphed (FIG. 1B).
- the embedded tissue is sectioned 3 ⁇ m thick, and anti-laminin 332 antibody (preparation: BM165, mouse monoclonal antibody), anti-laminin 511 antibody (4C7, Abacam, Cambridge, UK), and anti- ⁇ 1 integrin antibody (distributor: P5D2, Santa Cruz, CA) was used as the primary antibody, and staining was performed using Alexa488-labeled anti-mouse IgG antibody (distributor: Lifetechnologies, Carlsbad, CA) as the secondary antibody. Furthermore, nuclear staining was performed using DAPI. Visualization was performed using an Olympus BX51 microscope, and images were acquired with a DP control digital camera.
- FIG. 2A shows the staining results of the test subject in their 20s and the face and abdomen in their 60s.
- keratinocytes obtained from subjects of each age were separated and collected, and mRNA was extracted and purified using RNeasy mini kit (QIAGEN, Tokyo, Japan) according to the product instructions.
- the expression level of the laminin ⁇ 5 gene in keratinocytes was quantitatively PCR using Platinum SYBR Green qPCR super MIX-UDG (Invitrogen Japan, Tokyo Jaqpan).
- the primers used are as follows: The change in the expression level in each age is shown in FIG. 2B. From the results of FIGS. 1A to 1C and FIGS. 2A and 2B, it was found that the expression levels of laminin 551 and ⁇ 1 integrin and the number of epidermal basal stem cells showed the same tendency with respect to aging and ultraviolet rays.
- Example 2 Relationship between laminin 511 and stem cell marker Primeria flask coated with human epidermal keratinocytes with iMatrix-511 (Wako Pure Chemical Industries, Ltd.) using Humedia-KG2 medium (Kurabo Col, Ltd, Japan) Cultured in (Coaster, Tokyo, Japan) for 6 days. As a control, it was cultured in an uncoated flask. Cells grown to sub-confinence were detached with Typsin (Nakarai co, ltd, Japan), seeded on a chamber slide (Thermo Fisher Science, Waltham, MA) coated with iMatrix-511, and cultured. The control group was cultured on an uncoated chamber slide.
- MCSP antibody MAB2029, Chemicon, Billerica, MA
- Alexa488-labeled anti-mouse IgG antibody (Lifetechnologies, Carlsbad, CA) was used as the secondary antibody. Stained. Furthermore, nuclear staining was performed using DAPI. Visualization was performed using an Olympus BX51 microscope, and images were acquired with a DP control digital camera. It was found that more MCSP positive cells were maintained in the iMatrix511 coated group compared to the uncoated control (FIG. 3A).
- the medium was discarded and washed with PBS.
- MRNA was extracted and purified from the collected cells using RNeasy mini kit (QIAGEN, Tokyo, Japan) according to the product instructions.
- Quantitative PCR was performed using Platinum SYBR Green qPCR super MIX-UDG (Invitrogen Japan, Tokyo Jaqpan) in order to measure the expression levels of the genes of stem cell markers CD46, DLL1, Lrig1 and CD44.
- the primers used are as follows: Compared with the expression levels of CD46, DLL1, Lrig1 and CD44 genes in the control, the laminin 511 coat group increased the expression levels of CD46, DLL1, Lrig1 and CD44 genes (FIG. 3B). It was shown to contribute to the maintenance of stem cells.
- Example 3 Maintenance of the number of MCSP positive epidermal basal stem cells by addition of a laminin degradation inhibitor
- a skin sample of the abdomen of subjects (20s to 30s) who performed informed consent was obtained.
- the obtained sample was cultured for 4 days in a culture medium containing CGS270234 (10 ⁇ M) which is an MMP9 inhibitor and BIPBIU (10 ⁇ M) which is a heparanase inhibitor.
- the culture medium used was William's E medium (Thermo Fisher Science, Waltham, MA).
- CGS270234 and BIPBIU are compounds represented by the following chemical formulas, respectively, and are known to be usable as MMP9 inhibitors and heparanase inhibitors (Iriyama S, et al., Exp Dermatol. 2011; 20 (11): 953-5). Skin samples before culture, samples after 4 days culture (control: equivalence of DMSO solvent), and samples after 4 days culture (drug addition) were fixed with cold acetone according to AMex method and paraffined Embedded.
- the embedded tissue was cut into 3 ⁇ m sections, anti-laminin 551 antibody (4C7, Abacam, Cambridge, UK) was used as the primary antibody, and then Alexa488-labeled anti-mouseIgG antibody (distributor: Lifetechnologies, Carlsbad, CA). Furthermore, nuclear staining was performed using DAPI. The results are shown as FIG. Next, the embedded skin sample was treated with anti-MCSP antibody (MAB2029, Chemicon, Billerica, MA) as the primary antibody, and then with Alexa488-labeled anti-mouse IgG antibody (Lifetechnologies, Carlsbad, CA) as the secondary antibody. And co-stained. Furthermore, nuclear staining was performed using DAPI. A result is shown as FIG.4 (B).
- Example 4 Screening for a drug having a laminin 511 production promoting effect
- Epidermal cells obtained from fetuses were used with iMatrix-511 (Wako Pure Chemical Industries, Ltd.) using Humedia-KG2 medium (Kurabo Col, Ltd, Japan).
- the cells were cultured for 6 days in a coated Primeria flask (Coaster, Tokyo, Japan). When the cells became subconfluent, the cells were detached with Trypsin, seeded on a 6-well plate, replaced with a medium in which the candidate drug was dissolved after 1 day, and cultured for 48 hours.
- candidate drugs 178 cosmetics registered raw materials (breakdown: 135 extracts and 43 single compounds) were used.
- the medium was discarded, washed with PBS, and mRNA was extracted and purified from RNeasy mini kit (QIAGEN, Tokyo, Japan) according to the product instructions.
- the expression level of laminin ⁇ 5, laminin ⁇ 1, and laminin ⁇ 1 gene was quantitatively PCR using Platinum SYBR Green qPCRsuper MIX-UDG (Invitrogen Japan, Tokyo Jaqpan).
- the primers used are as follows: Algerex (Ichimaru Falcos Co., Ltd.) is a candidate drug that increased all the expression levels of laminin ⁇ 5, laminin ⁇ 1, and laminin ⁇ 1 compared to the expression levels of laminin ⁇ 5, laminin ⁇ 1, and laminin ⁇ 1 in the control. Company).
- the screened Algerex was tested by changing the drug concentration to 0.001%, 0.01%, and 0.10% to examine the dose-dependent laminin 511 expression promoting effect.
- the cells, culture medium, culture conditions, and PCR conditions used were the same as those used in the drug screening method of Example 4. The result is shown in FIG. 5A.
- protein quantitative analysis was performed by ELISA using an anti-laminin 511 antibody (distributor: cloud-clone corp) under the same conditions. The result is shown in FIG. 5B.
- Example 5 Verification of skin improvement function by Algerex Epidermal cells obtained from fetuses were coated with iMatrix-511 (Wako Pure Chemical Industries, Ltd.) using Humedia-KG2 medium (Kurabo Col, Ltd, Japan). Incubated in Primeria flask (Coaster, Tokyo, Japan). When the cells became subconfluent, the cells were detached with Trypsin, seeded on a 6-well plate, replaced with a medium containing 0.01% Argelex after 1 day, and cultured for 48 hours. As a control, a medium containing no Argelex was used.
- HPA heparanase
- PDGF-BB PDGF-BB gene
- HAS2 hyaluronic acid synthase 2
- HYAL1 hyaluronidase 1
- IL-8 interleukin 8
- HPA heparanase
- Example 6 Inhibition of HEI laminin degradation and maintenance effect of MCSP-positive epidermal basal stem cells
- HEI 0.01% 1- (2-hydroxyethyl) -2-imidazolidinone
- the control was cultured using a culture medium without addition of HEI.
- the cultured skin samples were fixed with cold acetone according to the AMex method and embedded in paraffin.
- the embedded tissue is cut into 3 ⁇ m sections and stained with MCSP antibody (MAB2029, Chemicon, Billerica, MA) as the primary antibody and Alexa488-labeled anti-mouse IgG antibody (Lifetechnologies, Carlsbad, CA) as the secondary antibody. did. Further, nuclear staining was performed using DAPI, and anti-laminin 551 antibody (4C7, Abacam, Cambridge, UK) was used as a primary antibody, and Alexa 488-labeled anti-mouse IgG antibody (Lifetechnologies, Carlsbad, CA) was used as a secondary antibody. And stained. It visualized using Olympus BX51 microscope, the image was acquired with the DP control digital camera, and was shown to FIG. 7A.
- MCSP antibody MAB2029, Chemicon, Billerica, MA
- Alexa488-labeled anti-mouse IgG antibody (Lifetechnologies, Carlsbad, CA) as the secondary antibody. did.
- nuclear staining was
- laminin 511 is decreased and the number of MCSP positive cells is also decreased in the control.
- the amount of laminin 511 could be maintained, and the number of MCSP positive cells on the basement membrane could be maintained.
- Example 7 Heparanase Inhibitory Effect of HEI Heparanase assay was performed using heparan sulfate immobilized plates described in Behzad F, et al., Analytical Biochemistry, 320, pp.207-213, 2003. Specifically, heparan sulfate was prepared by reacting heparan sulfate (Sieikagaku, Tokyo, Japan) with Photo-biotin. Biotinylated heparan sulfate was immobilized on a carbohydrate binding surface plate (Coastar, Tokyo, Japan).
- A431 cell lysate (50 ⁇ g / ml) along with 0% HEI, 0.0005% HEI, 0.005% HEI, and 0.05% HEI were added onto biotinylated heparan sulfate immobilized plates for 3 hours at 37 ° C. And then washed with PBS-T. Then, it incubated with peroxidase-avidin (Vector Laboratories, Inc. CA, USA) at 37 degreeC for 1 hour. 3,3 ′, 5,5′-tetramethylbenzidine (TMB) solution (Bio-Rad, Tokyo, Japan) was added and the plate was further incubated at room temperature for 30 minutes. Absorbance at 450 nm was measured to determine the inhibitory effect of heparanase. HEI was shown to inhibit heparanase activity in a dose-dependent manner (FIG. 8).
- Example 8 MMP9 Inhibitory Action of HEI MMP9 assay was performed using Matrix Metalloproteinase-9 (MMP-9) colorimetric drug discovery kit (Enzo life sience Inc.). Specifically, HEI was added to a solution of recombinant human MMP-9 enzyme so as to be 0.0001%, 0.001%, and 0.01%. After mixing the chromogenic MMP-9 substrate, the absorbance at 412 nm was measured every other minute. From the slope of absorbance (OD / min), the MMP-9 inhibition rate (%) of HEI was calculated. HEI was shown to inhibit the activity of MMP9 in a dose-dependent manner (FIG. 9).
- MMP-9 Matrix Metalloproteinase-9
- Example 9 Effect of HEI on improving the epidermis Skin samples of the abdomen of subjects (20s to 30s) who performed informed consent were obtained.
- the obtained sample was cultured for 5 days in a culture medium containing 0.01% HEI.
- the culture medium used was William's E medium (Thermo Fisher Science, Waltham, MA).
- the control was cultured using a culture medium without addition of HEI.
- Excess water adhering to the cultured skin sample was wiped off with a Kim towel and allowed to settle for 5 minutes. Then, TEWL was measured using a Vapometer, and the stratum corneum water content was measured using a Corneometer. The results are shown in FIGS. 10B and C.
- the cultured skin sample was fixed with cold acetone according to the AMex method and embedded in paraffin.
- the embedded tissue is cut into 3 ⁇ m sections, and filaggrin antibody (distributor: AKH-1, Santa CruzBiotechnology, Dallas, TX) is used as the primary antibody, and Alexa488-labeled anti-mouseIgG antibody (Lifetechnologies, Carlsbad, CA) is used as the secondary antibody. ). Furthermore, nuclear staining was performed using DAPI. Visualized with an Olympus BX51 microscope, the image was acquired with a DP control digital camera and shown in FIG. 10A.
- Example 10 Change of collagen just below basement membrane by addition of MMP inhibitor and heparanase inhibitor
- Skin tissue purchased from Bio Predic was used as a skin tissue piece, and CGS27023A (final concentration 10 -5 M) and BIPBIPU (final concentration 10) -5 cultured in William's E medium supplemented with M). In the control, culture was carried out without these inhibitors. The medium was changed every day, and skin tissue pieces were collected on the fifth day of culture. The collected skin tissue pieces were immersed in Zamboni fixative and postfixed with 1% osmium. Skin samples were embedded with epoxy resin. Ultrathin sections were prepared and observed with a transmission electron microscope (JEOL JEM1230) (FIG. 11A).
- Example 11 Expression of type V collagen Skin purchased from Bio Predic was subjected to the AMeX method to create paraffin blocks. Sections were prepared with a thickness of 3 ⁇ m, and an antibody against type V collagen (ORIGENE, Cat #: AM1015PU-N) and an antibody against cytokeratin 14 (K-14) (Fitzgerald, Cat #; 20R-CP002) were used. Fluorescent immunostaining was performed (FIG. 12A). The basement membrane region was stained with cytokeratin 14, and it was shown that type V collagen was present immediately below, and the amount decreased with aging.
- Normal human epidermal cells and normal human fibroblasts were purchased from Kurabo and Bio Predic. 6 samples obtained from subjects in their 20s to 30s and 6 samples obtained from subjects in their 50s to 60s were purchased. Epidermal cells were cultured in serum-free medium Humedia-KG2, and fibroblasts were cultured in DMEM medium containing 10% serum. After one passage, each sample was seeded on a 6-well plate. After becoming confluent, each cell was collected, cDNA was prepared, and the gene expression level of the V-type collagen gene COL5A1 was evaluated by real-time PCR using the following primers (FIG. 12B). It was shown that type V collagen is not expressed from epidermal cells but expressed from fibroblasts, and its expression level decreases with aging.
- Skin tissue purchased from Bio Predic was used as a skin tissue piece and cultured in William's E medium supplemented with CGS27023A (final concentration 10 -5 M) and BIPBIPU (final concentration 10 -5 M). In the control, culture was carried out without these inhibitors. The medium was changed every day, and skin tissue pieces were collected on the fifth day of culture. The collected skin tissue pieces were subjected to the AMeX method to prepare paraffin blocks. Sections were prepared with a thickness of 3 ⁇ m, and an antibody against type V collagen (ORIGENE, Cat #: AM1015PU-N) and an antibody against cytokeratin 14 (K-14) (Fitzgerald, Cat #; 20R-CP002) were used. Fluorescent immunostaining was performed (FIG. 13A).
- EFT-400 A three-dimensional skin model (EFT-400) purchased from MatTeK was cultured in a dedicated medium (EFT400-ASY) supplemented with CGS27023A (final concentration 10 ⁇ 5 M) and BIPBIPU (final concentration 10 ⁇ 5 M). In the control, culture was carried out without these inhibitors. The medium was changed once every two days, and the tissue piece was collected on the seventh day and subjected to the AMeX method to prepare a paraffin block. Sections were prepared with a thickness of 3 ⁇ m, and an antibody against type V collagen (ORIGENE, Cat #: AM1015PU-N) and an antibody against cytokeratin 14 (K-14) (Fitzgerald, Cat #; 20R-CP002) were used. Fluorescent immunostaining was performed (FIG. 13A).
- the three-dimensional skin model was cultured for 4 days and 7 days in the group with and without the inhibitor added (control), respectively. After culture, the epidermis was peeled off, and only the dermis was placed in Trizol to extract mRNA. CDNA was quickly prepared, and the gene expression level of the C-type collagen COL5A1 gene was evaluated by real-time PCR using the primers described above (FIG. 13B).
- FIG. 13C In the TEM image of Example 10, attention was paid to fibroblasts existing directly under the basement membrane (FIG. 13C). In the control of FIG. 13C (group not added with the inhibitor), collagen fibers are not often observed in the fibroblasts, whereas in the inhibitor-added group, collagen fibers are observed in the vesicles in the fibroblasts. This vesicle is suggested to be a collagen secretion process. This suggests that the fibroblasts directly under the basement membrane are actively producing collagen by the addition of the MMP inhibitor and heparanase inhibitor.
- a three-dimensional skin model (EFT-400) purchased from MatTeK was cultured in a dedicated medium (EFT400-ASY) supplemented with CGS27023A (final concentration 10 ⁇ 5 M) and BIPBIPU (final concentration 10 ⁇ 5 M). In the control, culture was carried out without these inhibitors. Culture supernatants on the 2nd, 4th and 7th days of culture were collected. Separately, skin-derived normal human fibroblasts collected from a 14-month-old child purchased from Bio Predic were cultured from a culture of a three-dimensional skin model into a culture cultured in DMEM supplemented with 10% FBS for 24 hours. The culture supernatant was added.
- Example 12 Search for factors that promote the expression of type V collagen Collagen model 3D skin (EFT-400) purchased from MatTeK was used as CGS27023A (final concentration 10 -5 M) and BIPBIPU (final concentration 10 -5 M). The cells were cultured in the added special medium (EFT400-ASY). The epidermis was collected from the skin model on the 2nd, 4th, and 7th days of culture, and a protein extract was prepared using RIPA buffer manufactured by Nacalai. Abcam's membrane array kit (ab134002) was used to detect the amount of various cytocans in the protein extract using LAS-1000UVmini manufactured by FUJIFILM, and a numerical graph was created using the attached software (data not shown) Published). Compared to controls, increased amounts of cytokines were selected as candidate cytokines that promote type V collagen expression. As such candidate cytokines, three types of cytokines including PDGF-BB were selected.
- cytokine proteins selected from R & D were purchased.
- PDGF-BB significantly increased type V collagen production.
- PDGF-BB is considered to be a cytokine produced from the epidermis side and a factor that acts on fibroblasts directly under the basement membrane and promotes expression of collagen V.
- Example 13 PDGF-BB action site and PDGF-BB expression change
- a section was prepared with a thickness of 3 ⁇ m, and an antibody against PDGFR- ⁇ (R & D Systems) Cat #; MAB1263) and antibodies against cytokeratin 14 (K-14) (Fitzgerald, Cat #; 20R-CP002) were subjected to fluorescent immunostaining (FIG. 16A). It was found that there are many cells expressing PDGFR- ⁇ directly under the basement membrane regardless of age. Thereby, it was confirmed that PDGF-BB secreted from the basement membrane or epidermal side can act on fibroblasts directly under the basement membrane.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Abstract
Description
[1] 表皮細胞におけるラミニン511の発現量を指標とする、ラミニン511発現促進剤のスクリーニング方法。
[2] 候補薬剤を含む培養培地中で表皮細胞を培養する工程、
表皮細胞におけるラミニン511の発現量を測定する工程、
対照におけるラミニン511発現量と比較して、ラミニン511の発現が増加した場合に、候補薬剤がラミニン511発現促進効果を有すると判定する工程
を含む、項目1に記載の方法。
[3] 前記ラミニン511の発現量が、ラミニン511のタンパク質量又はラミニンα5のmRNA量、ラミニンβ1のmRNA量、及びラミニンγ1のmRNA量からなる群から選ばれる1以上のmRNA量から決定される、項目1又は2に記載の方法。
[4] ラミニン511の発現量が、ラミニンα5のmRNA量、ラミニンβ1のmRNA量、及びラミニンγ1のmRNA量の合計量から決定される、項目1~3のいずれか一項に記載の方法。
[5] 前記ラミニン511発現促進剤が、表皮基底膜安定化剤である、項目1~4のいずれか一項に記載の方法。
[6] 表皮基底膜安定化剤が、表皮基底幹細胞の減少抑制又は増加剤である、項目1~5のいずれか一項に記載の方法。
[7] 表皮細胞が表皮幹細胞を含む、項目1~6のいずれか一項に記載の方法。
[8] 表皮幹細胞が表皮基底幹細胞を含む、項目1~7のいずれか一項に記載の方法。
[9] 表皮細胞がMCSP発現細胞を含む、項目1~8のいずれか一項に記載の方法。
[10] 表皮細胞が、さらにインテグリンを発現している細胞を含む、項目1~9のいずれか一項に記載の方法。
[11] 表皮細胞が胎児由来である、項目1~10のいずれか一項に記載の方法。
[12] 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンを有効成分とする、ラミニン511の発現促進剤。
[13] 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンを有効成分とする、ラミニン511の発現促進による表皮基底膜安定化剤。
[14] 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンを有効成分とする、ラミニン511の発現促進による表皮基底幹細胞の減少抑制又は増加剤。
[15] 1-(2-ヒドロキシエチル)-2-イミダゾリジノンを含む、細胞外マトリックス分解酵素の活性阻害剤。
[16] 細胞外マトリックス分解酵素が、マトリックスメタロプロテイナーゼ又はヘパラナーゼである、項目15に記載の細胞外マトリックス分解酵素の活性阻害剤。
[17] 細胞外マトリックス分解酵素が、マトリックスメタロプロテイナーゼ9である、項目15に記載の細胞外マトリックス分解酵素の活性阻害剤。
[18] 項目15~17のいずれか一項に記載の細胞外マトリックス分解酵素の活性阻害剤を含む、ラミニン511分解抑制剤。
[19] 項目15~17のいずれか一項に記載の細胞外マトリックス分解酵素の活性阻害剤を含む、表皮基底膜安定化剤。
[20] 項目15~17のいずれか一項に記載の細胞外マトリックス分解酵素の活性阻害剤を含む、表皮基底幹細胞減少抑制又は増加促進剤。
[21] 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンを投与することを含む、表皮においてラミニン511の発現を亢進方法。
[22] 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンを投与し、ラミニン511の発現促進作用によって、表皮基底膜を安定化する方法。
[23] 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンを投与し、ラミニン511の発現促進作用によって、表皮基底幹細胞の減少を抑制するか又は増加を促進する方法。
[24] 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンを投与し、表皮においてラミニン511の発現を亢進させる、美容方法。
[25] 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンを投与し、表皮においてラミニン511の発現を亢進させ、ラミニン511の発現促進作用によって表皮基底膜を安定化する、美容方法。
[26] 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンを投与し、表皮においてラミニン511の発現を亢進させ、ラミニン511の発現促進作用によって表皮基底幹細胞の減少を抑制するか又は増加を促進する、美容方法。
[27] ラミニン511の発現促進するための化粧品又は医薬品を製造のための、褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンの使用。
[28] 表皮基底膜を安定化するための化粧品又は医薬品を製造のための、褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンの使用。
[29] 表皮基底幹細胞の減少を抑制するか又は増加を促進するための化粧品又は医薬品を製造のための、褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンの使用。
[30] ラミニン511の発現促進を介して抗老化治療に用いるための褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノン。
[31] 表皮基底膜安定化を介して抗老化治療に用いるための褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノン。
[32] 表皮基底幹細胞の減少抑制又は増加を介して抗老化治療にもちいるための褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノン。
[33] 細胞外マトリックス分解酵素の活性阻害を介して抗老化治療にもちいるための1-(2-ヒドロキシエチル)-2-イミダゾリジノン。
[34] 細胞外マトリックス分解酵素が、マトリックスメタロプロテイナーゼ又はヘパラナーゼである、項目33に記載の1-(2-ヒドロキシエチル)-2-イミダゾリジノン。
[35] 細胞外マトリックス分解酵素が、マトリックスメタロプロテイナーゼ9である、項目33に記載の1-(2-ヒドロキシエチル)-2-イミダゾリジノン。
[36] 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキスを含む、皮膚バリア、ハリ、潤い、及び炎症の改善剤。
[37] 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキスを含む、炎症抑制剤。
[38]皮膚バリア、ハリ、潤い、及び炎症の改善剤の製造のための、褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキスの使用。
[39]炎症抑制剤の製造のための、褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキスの使用。
[40]褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキスを含む化粧料を皮膚バリア、ハリ、潤い、及び炎症の改善を必要とする対象に適用することを含む、皮膚バリア、ハリ、潤い、及び炎症の改善のための美容方法。
[41]炎症を患う対象に褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキスを含む化粧料を適用することを含む、炎症抑制のための美容方法。
候補薬剤を含む培養培地で表皮細胞を培養する工程、
表皮細胞におけるラミニン511の発現を測定する工程、
対照におけるラミニン511発現量と比較して、ラミニン511の発現が増加した場合に、候補薬剤がラミニン511発現促進効果を有すると判定する工程
を含む。さらに、培養表皮細胞に対し、紫外線を照射する工程を含んでもよい。紫外線の照射により、ラミニン511の発現量は減少する。紫外線の照射は、一例として、培養細胞に対し、1mJ/cm2~200mJ/cm2で照射することにより行われうる。紫外線の照射は、マトリクスメタロプロテイナーゼの活性を増強し、ラミニンの分解をもたらしうる。よって紫外線照射下において、候補薬剤が、ラミニン511のタンパク質量の減少を抑制できる場合には、候補薬剤がラミニン511の分解抑制効果および発現促進効果を有することがわかる。候補薬剤によるマトリクスメタノプロテイナーゼの活性に対する阻害効果を調べることで、候補薬剤がラミニン511の発現促進効果を有することを決定することができる。
サンプル
インフォームドコンセントを行った20代から70代の被験者(20代:9名、30代:10名、40代:10名、50代::9名、60代:10名、及び70代:9名)の顔面及び腹部の皮膚サンプルを取得し、AMex法に従って冷アセトンを用いて固定し、そしてパラフィンに包埋した。
ケラチノサイトにおけるMCSP遺伝子の発現量を、Platinum SYBR Green qPCRsuper MIX-UDG (Invitrogen Japan, Tokyo Jaqpan)を用いて定量的PCRを行った。使用したプライマーは下記の通りである:
ヒト表皮ケラチノサイトを、Humedia-KG2培地(Kurabo Col, Ltd, Japan)を用い、iMatrix-511(和光純薬工業株式会社)でコートされたPrimeria フラスコ(Coaster, Tokyo, Japan)中で6日培養した。対照として、未コートのフラスコ中で培養した。サブコンフレントまで増殖した細胞をTypsin(Nakarai co, ltd, Japan)で剥がし、iMatrix-511でコートしたchamber slide(Thermo Fisher Science, Waltham, MA)に播種し、培養した。対照群は、未コートのchamber slideで培養した。
インフォームドコンセントを行った被験者(20代から30代)の腹部の皮膚サンプルを取得した。取得されたサンプルをMMP9阻害剤であるCGS270234(10μM)及びヘパラナーゼ阻害剤であるBIPBIU(10μM)を含む培養培地で4日間培養した。培養培地は、William‘s E培地( Thermo Fisher Science, Waltham, MA)を用いた。CGS270234及びBIPBIUは、それぞれ下記の化学式により表される化合物であり、MMP9阻害剤及びヘパラナーゼ阻害剤として使用できることが知られている(Iriyama S, et al., Exp Dermatol. 2011; 20 (11): 953-5)。
胎児から取得された表皮細胞を、Humedia-KG2培地(Kurabo Col, Ltd, Japan)を用い、iMatrix-511(和光純薬工業株式会社)でコートされたPrimeria フラスコ(Coaster, Tokyo, Japan)中で6日間培養した。細胞がサブコンフルエントになったら、Trypsinで細胞を剥がし、6well plateに播種し、1日後に候補薬剤を溶解した培地に置換し、48時間培養を行った。候補薬剤として、化粧品登録原料178品(内訳:エキス類135品及び単品化合物43品)を用いた。培地を捨て、PBSで洗浄し、mRNAを、RNeasy mini kit (QIAGEN, Tokyo, Japan)を、製品説明書に従って抽出・精製した。ラミニンα5、ラミニンβ1、及びラミニンγ1遺伝子の発現量を、Platinum SYBR Green qPCRsuper MIX-UDG (Invitrogen Japan, Tokyo Jaqpan)を用いて定量的PCRを行った。使用したプライマーは下記の通りである:
胎児から取得された表皮細胞を、Humedia-KG2培地(Kurabo Col, Ltd, Japan)を用い、iMatrix-511(和光純薬工業株式会社)でコートされたPrimeria フラスコ(Coaster, Tokyo, Japan)中で培養した。細胞がサブコンフルエントになったら、Trypsinで細胞を剥がし、6well plateへ播種し、1日後に0.01%アルジェレックスを含む培地に置換し、48時間培養を行った。対照としては、アルジェレックスを含まない培地を用いた。培地を捨て、PBSで洗浄し、mRNAを、RNeasy mini kit (QIAGEN, Tokyo, Japan)を、製品説明書に従って抽出・精製した。ヘパラナーゼ(HPA)遺伝子、PDGF-BB遺伝子、ヒアルロン酸合成酵素2(HAS2)遺伝子、ヒアルロニダーゼ1(HYAL1)、及びインターロイキン8(IL-8)遺伝子の発現量を、Platinum SYBR Green qPCRsuper MIX-UDG (Invitrogen Japan, Tokyo Jaqpan)を用いて定量的PCRを行った。使用したプライマーは下記の通りである:
インフォームドコンセントを行った被験者(20代から30代)の腹部の皮膚サンプルを取得した。取得されたサンプルを0.01%1-(2-ヒドロキシエチル)-2-イミダゾリジノン(HEI、又はS-173)を含む培養培地で5日間培養した。培養培地は、William‘s E培地(Thermo Fisher Science, Waltham, MA )を用いた。対照は、HEIを添加しない培養培地を用いて培養した。培養後の皮膚サンプルを、AMex法に従って冷アセトンを用いて固定し、そしてパラフィンに包埋した。
ヘパラナーゼアッセイを、Behzad F, et al., Analytical Biochemistry, 320, pp.207-213, 2003に記載されるヘパラン硫酸固定化プレートを用いて行った。具体的に、へパラン硫酸(Sieikagaku, Tokyo, Japan)を、Photo-ビオチンと反応させることにより、ビオチン化へパラン硫酸を調製した。ビオチン化ヘパラン硫酸を、炭水化物結合表面プレート(Coastar, Tokyo, Japan)上に固定した。A431細胞ライセート(50μg/ml)と共に、0%HEI、0.0005%HEI、0.005%HEI、及び0.05%HEIをビオチン化ヘパラン硫酸固定化プレート上に添加して、3時間37℃でインキュベートし、PBS-Tで洗浄した。その後、ペルオキシダーゼ―アビジン(Vector Laboratories, Inc. CA, USA)と37℃で1時間インキュベートした。3,3’,5,5’-テトラメチルベンジジン(TMB)溶液(Bio-Rad, Tokyo, Japan)を加え、そしてプレートをさらに室温で30分間インキュベートした。450nmでの吸光度を計測し、ヘパラナーゼの阻害作用を決定した。HEIは、用量依存的にヘパラナーゼの活性を阻害することが示された(図8)。
MMP9アッセイを、Matrix Metalloproteinase-9 (MMP-9) colorimetric drug discovery kit (Enzo life sience Inc.)を用いて行った。具体的に、recombinant human MMP-9 enzymeの溶液に、0.0001%, 0.001%, 0.01% となるようにHEIを加えた。chromogenic MMP-9 substrate混合後、1分おきに412nmの吸光度を測定した。吸光度の傾き(OD/min)から、HEIのMMP-9阻害率(%)を算出した。HEIは、用量依存的にMMP9の活性を阻害することが示された(図9)。
インフォームドコンセントを行った被験者(20代から30代)の腹部の皮膚サンプルを取得した。取得されたサンプルを0.01%HEIを含む培養培地で5日間培養した。培養培地は、William‘s E培地(Thermo Fisher Science, Waltham, MA )を用いた。対照は、HEIを添加しない培養培地を用いて培養した。培養後の皮膚サンプルに付着した余分な水分をキムタオルでふき取り、5分清置させた後に、Vapometerを用いてTEWLを測定し、Corneometerを用いて角層水分量を測定した。結果を図10B及びCに示す。また、培養後の皮膚サンプルを、AMex法に従って冷アセトンを用いて固定し、そしてパラフィンに包埋した。
Bio Predic社から購入した皮膚組織を皮膚組織片とし、CGS27023A(終濃度10-5M)及びBIPBIPU(終濃度10-5M)を添加したWilliam’s E培地中で培養した。対照ではこれらの阻害剤を含めないで培養を行った。培地を毎日交換し、培養5日目に皮膚組織片を回収した。回収した皮膚組織片をZamboni固定液に浸漬し、1%オスミウムで後固定した。皮膚試料はエポキシ樹脂で包埋した。超薄切片を作成し、透過型電子顕微鏡(JEOL JEM1230)にて観察した(図11A)。
Bio Predic社から購入した皮膚をAMeX法に供して、パラフィンブロックを作成した。3μmの厚さで切片を作成し、V型コラーゲンに対する抗体(ORIGENE社,Cat#:AM1015PU-N)及びサイトケラチン14(K-14)に対する抗体(Fitzgerald, Cat#;20R-CP002)を用いて蛍光免疫染色を行った(図12A)。基底膜領域がサイトケラチン14により染色されており、その直下において、V型コラーゲンが存在することが示され、加齢によりその量が減少した。
MatTeK社から購入した皮膚三次元モデル(EFT-400)を、CGS27023A(終濃度10-5M)、BIPBIPU(終濃度10-5M)を添加した専用培地(EFT400-ASY)中で培養した。培養2日目、4日目、7日目の皮膚モデルから表皮を回収し、ナカライ社製RIPA bufferを使って、たんぱく質抽出液を調製した。Abcam社製membrane array kit(ab134002)を用いて、たんぱく質抽出液中の各種サイトカン量をFUJIFILM社製LAS-1000UVminiを用いて検出し、付属のソフトウエアにて数値化しグラフを作成した(データ未掲載)。対照に比較して、量が増大したサイトカインを、V型コラーゲン発現を促進する候補サイトカインとして選別した。かかる候補サイトカインとして、PDGF-BBを含む3種のサイトカインを選別した。
し、TrizolにてmRNAを抽出した。速やかにcDNAを作成し、上述のプライマーを用いて、リアルタイムPCRによりV型コラーゲンの遺伝子COL5A1の遺伝子発現量を評価した(図15)。3種のサイトカインの中で、PDGF-BBのみが、V型コラーゲン産生を有意に増加させた。これにより、PDGF-BBが、表皮側から産生されるサイトカインであって、基底膜直下の線維芽細胞に作用してV型コラーゲン発現を促進する因子であると考えられる。
実施例11と同様にして取得されたパラフィンブロックについて、3μmの厚さで切片を作成し、PDGFR-βに対する抗体(R&D Systems, Cat#;MAB1263)及びサイトケラチン14(K-14)に対する抗体(Fitzgerald, Cat#;20R-CP002)を用いて蛍光免疫染色を行った(図16A)。年齢によらず、基底膜直下に、PDGFR-βを発現する細胞が多く存在することが分かった。これにより、基底膜又は表皮側から分泌されたPDGF-BBが、基底膜直下の線維芽細胞に作用しうることが確かめられた。
Claims (22)
- 表皮細胞におけるラミニン511の発現量を指標とする、ラミニン511発現促進剤のスクリーニング方法。
- 候補薬剤を含む培養培地中で表皮細胞を培養する工程、
表皮細胞におけるラミニン511の発現量を測定する工程、
対照におけるラミニン511発現量と比較して、ラミニン511の発現量が増加した場合に、候補薬剤がラミニン511発現促進効果を有すると判定する工程
を含む、請求項1に記載の方法。 - 前記ラミニン511の発現量が、ラミニン511のタンパク質量又はラミニンα5のmRNA、ラミニンβ1のmRNA量、及びラミニンγ1のmRNA量からなる群から選ばれる1以上のmRNA量から決定される、請求項1又は2に記載の方法。
- ラミニン511の発現量が、ラミニンα5のmRNA量、ラミニンβ1のmRNA量、及びラミニンγ1のmRNA量の合計量から決定される、請求項1~3のいずれか一項に記載の方法。
- 前記ラミニン511発現促進剤が、表皮基底膜安定化剤である、請求項1~4のいずれか一項に記載の方法。
- 表皮基底膜安定化剤が、表皮幹細胞の減少抑制又は増加促進剤である、請求項1~5のいずれか一項に記載の方法。
- 表皮細胞が表皮幹細胞を含む、請求項1~6のいずれか一項に記載の方法。
- 表皮幹細胞が表皮基底幹細胞を含む、請求項1~7のいずれか一項に記載の方法。
- 表皮細胞がMCSP発現細胞を含む、請求項1~8のいずれか一項に記載の方法。
- 表皮細胞が、さらにインテグリンを発現している細胞を含む、請求項1~9のいずれか一項に記載の方法。
- 表皮細胞が胎児由来である、請求項1~10のいずれか一項に記載の方法。
- 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンを有効成分とする、ラミニン511の発現促進剤。
- 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンを有効成分とする、ラミニン511の発現促進による表皮基底膜安定化剤。
- 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキス又は1-(2-ヒドロキシエチル)-2-イミダゾリジノンを有効成分とする、ラミニン511の発現促進による表皮幹細胞の減少抑制又は増加促進剤。
- 1-(2-ヒドロキシエチル)-2-イミダゾリジノンを含む、細胞外マトリックス分解酵素の活性阻害剤。
- 細胞外マトリックス分解酵素が、マトリックスメタロプロテイナーゼ又はヘパラナーゼである、請求項15に記載の細胞外マトリックス分解酵素の活性阻害剤。
- 細胞外マトリックス分解酵素が、マトリックスメタロプロテイナーゼ9である、請求項15に記載の細胞外マトリックス分解酵素の活性阻害剤。
- 請求項15~17のいずれか一項に記載の細胞外マトリックス分解酵素の活性阻害剤を含む、ラミニン511分解抑制剤。
- 請求項15~17のいずれか一項に記載の細胞外マトリックス分解酵素の活性阻害剤を含む、表皮幹細胞の減少抑制又は増加促進剤。
- 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキスを皮膚バリア、ハリ、潤い、及び炎症の改善を必要とする対象に適用することを含む、皮膚バリア、ハリ、潤い、及び炎症の改善剤。
- 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキスを含む、IL-8発現抑制剤。
- 褐藻、紅藻、及び緑藻からなる群から選ばれる少なくとも1の抽出エキスを含む、炎症抑制剤。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780061763.9A CN109844128A (zh) | 2016-10-21 | 2017-10-20 | 层粘连蛋白511产生促进剂、表皮基底膜稳定剂和/或表皮干细胞减少抑制或增加促进剂的筛选方法 |
EP21162211.3A EP3878970A1 (en) | 2016-10-21 | 2017-10-20 | Laminin 511 production promoter, basal epidermal layer stabilizer and/or screening method for agent to minimize reduction in or promote increase in epidermal stem cells |
KR1020237006080A KR102631159B1 (ko) | 2016-10-21 | 2017-10-20 | 라미닌 511 생성 촉진제, 표피 기저막 안정화제 및/또는 표피 줄기 세포 감소 억제 또는 증가 촉진제의 스크리닝 방법 |
JP2018545781A JP7059193B2 (ja) | 2016-10-21 | 2017-10-20 | ラミニン511産生促進剤、表皮基底膜安定化剤及び/又は表皮幹細胞減少抑制又は増加促進剤のスクリーニング方法 |
US16/343,749 US11564959B2 (en) | 2016-10-21 | 2017-10-20 | Screening method for laminin 511 production promoting agent, basal epidermal layer stabilizing agent, and/or epidermal stem cells reduction inhibiting or proliferation promoting agent |
KR1020197004177A KR20190066001A (ko) | 2016-10-21 | 2017-10-20 | 라미닌 511 생성 촉진제, 표피 기저막 안정화제 및/또는 표피 줄기 세포 감소 억제 또는 증가 촉진제의 스크리닝 방법 |
KR1020247002902A KR20240014626A (ko) | 2016-10-21 | 2017-10-20 | 라미닌 511 생성 촉진제, 표피 기저막 안정화제 및/또는 표피 줄기 세포 감소 억제 또는 증가 촉진제의 스크리닝 방법 |
EP17862792.3A EP3530750A4 (en) | 2016-10-21 | 2017-10-20 | LAMININE 511 MANUFACTURING PROMOTER, BASAL EPIDERMAL LAYER STABILIZER, AND / OR SCREENING PROCEDURES FOR A MEANS OF MINIMIZING THE REDUCTION IN OR PROMOTING Elevation IN EPIDERMAL STEM CELLS |
JP2021182208A JP7328302B2 (ja) | 2016-10-21 | 2021-11-08 | ラミニン511産生促進剤、表皮基底膜安定化剤及び/又は表皮幹細胞減少抑制又は増加促進剤のスクリーニング方法 |
US18/068,406 US20230210928A1 (en) | 2016-10-21 | 2022-12-19 | Screening method for laminin 511 production promoting agent, basal epidermal layer stabilizing agent, and/or epidermal stem cells reduction inhibiting or proliferation promoting agent |
JP2023127301A JP2023133570A (ja) | 2016-10-21 | 2023-08-03 | ラミニン511産生促進剤、表皮基底膜安定化剤及び/又は表皮幹細胞減少抑制又は増加促進剤のスクリーニング方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016207027 | 2016-10-21 | ||
JP2016-207027 | 2016-10-21 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/343,749 A-371-Of-International US11564959B2 (en) | 2016-10-21 | 2017-10-20 | Screening method for laminin 511 production promoting agent, basal epidermal layer stabilizing agent, and/or epidermal stem cells reduction inhibiting or proliferation promoting agent |
US18/068,406 Division US20230210928A1 (en) | 2016-10-21 | 2022-12-19 | Screening method for laminin 511 production promoting agent, basal epidermal layer stabilizing agent, and/or epidermal stem cells reduction inhibiting or proliferation promoting agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018074606A1 true WO2018074606A1 (ja) | 2018-04-26 |
Family
ID=62019373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/038079 WO2018074606A1 (ja) | 2016-10-21 | 2017-10-20 | ラミニン511産生促進剤、表皮基底膜安定化剤及び/又は表皮幹細胞減少抑制又は増加促進剤のスクリーニング方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US11564959B2 (ja) |
EP (2) | EP3878970A1 (ja) |
JP (3) | JP7059193B2 (ja) |
KR (3) | KR20190066001A (ja) |
CN (1) | CN109844128A (ja) |
TW (1) | TWI823838B (ja) |
WO (1) | WO2018074606A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020164482A (ja) * | 2019-03-29 | 2020-10-08 | 丸善製薬株式会社 | ラミニン5産生促進剤、皮膚基底膜正常化剤及び皮膚損傷回復促進剤 |
WO2022131108A1 (ja) * | 2020-12-15 | 2022-06-23 | 株式会社 資生堂 | 真皮再生促進剤 |
WO2023100691A1 (ja) * | 2021-12-03 | 2023-06-08 | 株式会社 資生堂 | 幹細胞増殖促進剤 |
WO2023120204A1 (ja) * | 2021-12-21 | 2023-06-29 | 株式会社 資生堂 | 水中油型乳化化粧料 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111500629B (zh) * | 2020-04-17 | 2021-11-19 | 安徽中盛溯源生物科技有限公司 | 一种高表达层粘连蛋白-511变体的方法及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000080024A (ja) * | 1998-07-15 | 2000-03-21 | L'oreal Sa | 抗炎症組成物 |
WO2011040496A1 (ja) * | 2009-09-30 | 2011-04-07 | 株式会社資生堂 | ヘパラナーゼ活性阻害剤 |
JP2012097049A (ja) * | 2010-11-04 | 2012-05-24 | Hydrox Kk | 皮膚外用用組成物 |
JP2016030750A (ja) * | 2014-07-30 | 2016-03-07 | 株式会社マンダム | 皮膚外用剤 |
JP2016169238A (ja) * | 2008-03-31 | 2016-09-23 | 株式会社 資生堂 | しわを防止または改善するための経口、注射、皮膚外用剤および美容方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2746650A1 (de) | 1977-10-17 | 1979-04-26 | Henkel Kgaa | Kosmetische mittel mit einem gehalt an haut-feuchthaltemitteln |
JP4074043B2 (ja) * | 2000-03-27 | 2008-04-09 | 株式会社資生堂 | 皮膚基底膜形成促進剤、人工皮膚形成促進剤及び人工皮膚の製造方法 |
JP2003089628A (ja) * | 2001-09-18 | 2003-03-28 | Noevir Co Ltd | 皮膚外用剤 |
ES2594011T3 (es) * | 2006-09-26 | 2016-12-15 | Basf Beauty Care Solutions Llc | Extractos de Sarcodiotheca y biofermentaciones para su uso en productos cosméticos |
TW200908989A (en) * | 2007-08-27 | 2009-03-01 | Taiyen Biotech Co Ltd | Brown seaweed antiaging component |
TW200914061A (en) * | 2007-09-18 | 2009-04-01 | Meng-Han Shih | Method for using green algae extract to retard aging of skin cells and cosmetic composition containing green algae extract |
JP5744409B2 (ja) * | 2010-03-04 | 2015-07-08 | 株式会社 資生堂 | 人工皮膚 |
KR20130024563A (ko) * | 2011-08-31 | 2013-03-08 | 한국해양대학교 산학협력단 | 갈조류 감태의 n-부탄올 추출물 |
CN105902408B (zh) * | 2015-09-25 | 2019-02-05 | 上海百雀羚生物科技有限公司 | 含有褐藻和红藻精华的化妆品组合物 |
-
2017
- 2017-10-20 EP EP21162211.3A patent/EP3878970A1/en active Pending
- 2017-10-20 WO PCT/JP2017/038079 patent/WO2018074606A1/ja unknown
- 2017-10-20 KR KR1020197004177A patent/KR20190066001A/ko not_active IP Right Cessation
- 2017-10-20 US US16/343,749 patent/US11564959B2/en active Active
- 2017-10-20 KR KR1020247002902A patent/KR20240014626A/ko active Application Filing
- 2017-10-20 KR KR1020237006080A patent/KR102631159B1/ko active IP Right Grant
- 2017-10-20 EP EP17862792.3A patent/EP3530750A4/en active Pending
- 2017-10-20 CN CN201780061763.9A patent/CN109844128A/zh active Pending
- 2017-10-20 TW TW106136272A patent/TWI823838B/zh active
- 2017-10-20 JP JP2018545781A patent/JP7059193B2/ja active Active
-
2021
- 2021-11-08 JP JP2021182208A patent/JP7328302B2/ja active Active
-
2022
- 2022-12-19 US US18/068,406 patent/US20230210928A1/en active Pending
-
2023
- 2023-08-03 JP JP2023127301A patent/JP2023133570A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000080024A (ja) * | 1998-07-15 | 2000-03-21 | L'oreal Sa | 抗炎症組成物 |
JP2016169238A (ja) * | 2008-03-31 | 2016-09-23 | 株式会社 資生堂 | しわを防止または改善するための経口、注射、皮膚外用剤および美容方法 |
WO2011040496A1 (ja) * | 2009-09-30 | 2011-04-07 | 株式会社資生堂 | ヘパラナーゼ活性阻害剤 |
JP2012097049A (ja) * | 2010-11-04 | 2012-05-24 | Hydrox Kk | 皮膚外用用組成物 |
JP2016030750A (ja) * | 2014-07-30 | 2016-03-07 | 株式会社マンダム | 皮膚外用剤 |
Non-Patent Citations (2)
Title |
---|
IMANISHI, H. ET AL.: "Spatial and temporal control of laminin-332 and -511 expressions during hair morphogenesis", MED. MOL. MORPHOL., vol. 47, 2014, pages 38 - 42, XP055479738 * |
MUFFLER, S. ET AL.: "A Stable Niche Supports Long-Term Maintenance of Human Epidermal Stem Cells in Organotypic Cultures", STEM CELLS, vol. 26, 2008, pages 2506 - 2515, XP055479739 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020164482A (ja) * | 2019-03-29 | 2020-10-08 | 丸善製薬株式会社 | ラミニン5産生促進剤、皮膚基底膜正常化剤及び皮膚損傷回復促進剤 |
WO2022131108A1 (ja) * | 2020-12-15 | 2022-06-23 | 株式会社 資生堂 | 真皮再生促進剤 |
WO2023100691A1 (ja) * | 2021-12-03 | 2023-06-08 | 株式会社 資生堂 | 幹細胞増殖促進剤 |
WO2023120204A1 (ja) * | 2021-12-21 | 2023-06-29 | 株式会社 資生堂 | 水中油型乳化化粧料 |
Also Published As
Publication number | Publication date |
---|---|
TWI823838B (zh) | 2023-12-01 |
KR102631159B1 (ko) | 2024-01-30 |
KR20230035135A (ko) | 2023-03-10 |
US20230210928A1 (en) | 2023-07-06 |
EP3878970A1 (en) | 2021-09-15 |
JPWO2018074606A1 (ja) | 2019-09-05 |
JP2022010164A (ja) | 2022-01-14 |
JP7328302B2 (ja) | 2023-08-16 |
US11564959B2 (en) | 2023-01-31 |
TW201819909A (zh) | 2018-06-01 |
JP2023133570A (ja) | 2023-09-22 |
CN109844128A (zh) | 2019-06-04 |
KR20240014626A (ko) | 2024-02-01 |
EP3530750A1 (en) | 2019-08-28 |
JP7059193B2 (ja) | 2022-04-25 |
EP3530750A4 (en) | 2020-08-12 |
KR20190066001A (ko) | 2019-06-12 |
US20190275094A1 (en) | 2019-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7328302B2 (ja) | ラミニン511産生促進剤、表皮基底膜安定化剤及び/又は表皮幹細胞減少抑制又は増加促進剤のスクリーニング方法 | |
US11298372B2 (en) | Composition for ameliorating loss of hair and graying of hair, and use thereof | |
Parodi et al. | Autophagy is essential for maintaining the growth of a human (mini-) organ: Evidence from scalp hair follicle organ culture | |
JP5872158B2 (ja) | 皮膚美白方法、並びに、皮膚シミ形成抑制及び/又は除去因子のスクリーニング方法 | |
Coppe et al. | A role for fibroblasts in mediating the effects of tobacco-induced epithelial cell growth and invasion | |
Gueniche et al. | Efficacy of glucosamine sulphate in skin ageing: results from an ex vivo anti-ageing model and a clinical trial | |
TW201908728A (zh) | 抗老化物質之篩選方法 | |
US11311585B2 (en) | VE-cadherin expression promoting agent and/or integrin α5 expression promoting agent | |
Qiu et al. | SCF/c-kit signaling is required in 12-O-tetradecanoylphorbol-13-acetate-induced migration and differentiation of hair follicle melanocytes for epidermal pigmentation | |
WO2022131108A1 (ja) | 真皮再生促進剤 | |
WO2023100691A1 (ja) | 幹細胞増殖促進剤 | |
KR20170107331A (ko) | 콜라겐 발현 촉진 및 주름개선에 효과가 있는 화장료 개발 | |
Takabe | Hyaluronan and its role in melanomagenesis: from melanocytes to metastatic melanoma | |
JP6903675B2 (ja) | 皮膚細胞分化促進用組成物及び皮膚細胞分化促進物質のスクリーニング方法 | |
TW201922290A (zh) | 具有緊緻度改善作用之物質之篩選方法 | |
Stem | Technical File |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018545781 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17862792 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20197004177 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017862792 Country of ref document: EP Effective date: 20190521 |